…pharmacological basis Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of oral agents initially developed for glucose lowering in type 2 diabetes mellitus (T2DM)…

…cardiomyopathy, congestive heart failure, congenital heart disease, diabetes mellitus (both type 1 and type 2), obesity, smoking, obstructive sleep apnea and chronic obstructive pulmonary disease…

…and potassium should be evaluated within 1 to 2 weeks after initiation of ACE inhibitors, especially in patients with preexisting azotemia, hypotension, hyponatremia, diabetes mellitus…

…For decades, the management of type 2 diabetes mellitus (T2DM) and obesity was siloed, with clinicians focusing primarily on hemoglobin A1c (HbA1c) reduction, blood pressure…

…7] . The dominant risk factors for HFpEF include hypertension (present in 80% of cases), obesity, type 2 diabetes mellitus, chronic kidney disease (CKD), sedentary lifestyle…

…possible stent thrombosis for clinical research and outcome assessment. Predisposing factors Domain Factors associated with stent thrombosis Clinical Acute myocardial infarction, diabetes mellitus, renal failure…

…mosm/kg or total osmolality 320 mosm/kg Typical patient Often type 1 diabetes, but also occurs in type 2 diabetes Usually type 2 diabetes…

…or long acting) Covers fasting glucose production Everyone with type 1 diabetes, always, including while fasting. Many with type 2 Mealtime insulin (rapid acting) Covers…

…production Familial forms include familial hyperaldosteronism type 1, formerly termed glucocorticoid remediable aldosteronism, and other familial forms associated with adrenal adenoma or bilateral adrenal hyperplasia…

…and with or without an elevation in cardiac troponin. The underlying pathological mechanism is not restricted to a single lesion or process. Although Type 1…